Feature Reviews in Drug Discovery

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 8013

Special Issue Editor

Auckland Bioengineering Institute, University of Auckland, Auckland 1142, New Zealand
Interests: diabetes; obesity; cancer; non-communicalbe diseases; marine natural compounds; fucoidan; seaweed; clams; food chemistry; pharmacology; drug metabolism; pharmacokinetics; pre-clinical pharmacology; natural compound extraction; polyamine metabolism; marine bioactives
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry, pharmacology, and biotechnology. Chemical rational design, biological-target-based searching, natural compound screening, chemo-/bio-informatics, and metabolites from metabolomics are all ways used to discover new drugs. In addition, in vitro, in vivo, and clinical testing is the essential path for drug discovery. We aim to showcase the drug discovery field in our Biomedicines journal by launching this Special Issue. Review articles on topics related (but not limited) to the above-mentioned areas (including reviews on special individual compound/drug and/or target) are all welcome. Reviews have to most up-to-date and focus on the development of recent 10 years.

Prof. Dr. Jun Lu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug discovery
  • molecular target
  • screening
  • metabolite
  • rational design
  • omics
  • informatics
  • natural compounds

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 870 KiB  
Review
Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review
by Jung Yoon Jang, Donghwan Kim and Nam Deuk Kim
Biomedicines 2023, 11(6), 1635; https://doi.org/10.3390/biomedicines11061635 - 04 Jun 2023
Cited by 9 | Viewed by 4001
Abstract
Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact [...] Read more.
Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare expenditure, sarcopenia in the elderly has become a major focus of research and public policy debates worldwide. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice, partly owing to the lack of available diagnostic testing and uniform diagnostic criteria. Since the World Health Organization and the United States assigned a disease code for sarcopenia in 2016, countries worldwide have assigned their own disease codes for sarcopenia. However, there are currently no approved pharmacological agents for the treatment of sarcopenia; therefore, interventions for sarcopenia primarily focus on physical therapy for muscle strengthening and gait training as well as adequate protein intake. In this review, we aimed to examine the latest information on the epidemiology, molecular mechanisms, interventions, and possible treatments with new drugs for sarcopenia. Full article
(This article belongs to the Special Issue Feature Reviews in Drug Discovery)
Show Figures

Figure 1

25 pages, 1843 KiB  
Review
RNA Therapeutics: A Healthcare Paradigm Shift
by Sarfaraz K. Niazi
Biomedicines 2023, 11(5), 1275; https://doi.org/10.3390/biomedicines11051275 - 25 Apr 2023
Cited by 5 | Viewed by 3125
Abstract
COVID-19 brought about the mRNA vaccine and a paradigm shift to a new mode of treating and preventing diseases. Synthetic RNA products are a low-cost solution based on a novel method of using nucleosides to act as an innate medicine factory with unlimited [...] Read more.
COVID-19 brought about the mRNA vaccine and a paradigm shift to a new mode of treating and preventing diseases. Synthetic RNA products are a low-cost solution based on a novel method of using nucleosides to act as an innate medicine factory with unlimited therapeutic possibilities. In addition to the common perception of vaccines preventing infections, the newer applications of RNA therapies include preventing autoimmune disorders, such as diabetes, Parkinson’s disease, Alzheimer’s disease, and Down syndrome; now, we can deliver monoclonal antibodies, hormones, cytokines, and other complex proteins, reducing the manufacturing hurdles associated with these products. Newer PCR technology removes the need for the bacterial expression of DNA, making mRNA a truly synthetic product. AI-driven product design expands the applications of mRNA technology to repurpose therapeutic proteins and test their safety and efficacy quickly. As the industry focuses on mRNA, many novel opportunities will arise, as hundreds of products under development will bring new perspectives based on this significant paradigm shift—finding newer solutions to existing challenges in healthcare. Full article
(This article belongs to the Special Issue Feature Reviews in Drug Discovery)
Show Figures

Graphical abstract

Back to TopTop